CDK4 inhibitors for cancer treatment

PF-07220060, a selective CDK4 inhibitor, addresses the toxicity issues of current CDK4/6 inhibitors by providing effective cancer treatment with minimized adverse effects through specific dosing and combination therapies, enhancing tumor inhibition with endocrine agents.

JP2024542633APending Publication Date: 2024-11-15PFIZER INC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024532158
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-11-16
Filing Date
2022-11-29
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Current CDK4/6 inhibitors used in cancer therapy are associated with dose-limiting hematologic toxicities, particularly neutropenia, and there is a need for appropriate dosing regimens that minimize adverse events while effectively treating cancer.

Method used

The use of PF-07220060, a selective CDK4 inhibitor, in single agent and combination therapies with endocrine therapeutic agents like aromatase inhibitors or selective estrogen receptor modulators, administered in specific dosages and schedules to treat cancer, minimizing adverse effects.

Benefits of technology

PF-07220060 demonstrates potential to reduce dose-limiting neutropenia and achieve higher tolerated plasma concentrations, showing efficacy in inhibiting CDK4 oncogenes in tumors, with additive or synergistic benefits when combined with endocrine therapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542633000001_ABST
    Figure 2024542633000001_ABST
Patent Text Reader

Abstract

The present disclosure provides a method of treating cancer comprising administering a therapeutically effective amount of PF-07220060 to a subject in need of such treatment. The present disclosure also provides a method of treating cancer comprising administering a therapeutically effective amount of PF-07220060 and an endocrine therapy to a subject in need of such treatment. [Diagram 2] TIFF2024542633000012.tif73161
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure relates to the therapeutic treatment of cancer using a cyclin-dependent kinase (CDK) inhibitor, 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1H-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-D-threo-pentitol (hereinafter PF-07220060) or a pharma-ceutically acceptable salt thereof, alone as monotherapy or in combination with endocrine therapy. The present invention also relates to related combination therapies, pharmaceutical compositions, and pharmaceutical uses. [Background technology]

[0002] CDKs are important cellular enzymes that play essential functions in regulating eukaryotic cell division and proliferation. CDK inhibitors may be useful in the treatment of proliferative disorders, including cancer.

[0003] Cancer develops due to unregulated cell proliferation, which is brought about by unregulated progression through the cell cycle and loss of checkpoint control, allowing subsequent uncontrolled cell proliferation. Rb1 (retinoblastoma protein) is a key negative regulator throughout the G1 and quiescent G0 phases of the cell cycle, until or unless it is phosphorylated by CDK4 or CDK6. (Weinberg, RA, The retinoblastoma protein and cell cycle control. Cell, vol. 81, pp. 323-330, 1995). The concept of dysregulation of the CDK4 / 6-retinoblastoma protein axis in cancer is supported by genetic alterations commonly identified in breast cancer, such as amplification of the cyclin D1 (CCND1) and cyclin E1 (CCNE1) genes, as well as alterations in the endogenous CDK4-cyclin D1 inhibitor p16 (INK4a, encoded by the CDKN2A gene), TP53 and PIK3CA genes. (Cancer Genome Atlas Network.Comprehensive genomic characterization of human breast tumors.Nature, 490, 61-70, 2012).

[0004] CDK4 / 6 inhibition has emerged as a promising strategy for cancer therapy, especially for the treatment of endocrine-resistant BC. (Rani, A. et al., Endocrine Resistance in Hormone Receptor Positive Breast Cancer-From Mechanism to Therapy. Front Endocrinol (Lausanne) 10:245, 2019). CDK4 / 6 inhibitors (e.g., palbociclib, abemaciclib, ribociclib) significantly improved progression-free survival and / or overall survival in patients with HR-positive / HER2-negative metastatic breast cancer when administered in combination with endocrine therapy. (Spring, LM et al., Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet, 395, 817-827, 2020).

[0005] CDK4 / 6 inhibitors enhance response rates and prolong disease control in patients with HR+, HER2- breast cancer but are associated with dose-limiting hematologic toxicities, primarily neutropenia.

[0006] PF-07220060 is a potent inhibitor of cyclin-dependent kinase 4 (CDK4). The preparation of PF-07220060 is described in International Patent Publication No. WO2019 / 207463 and U.S. Patent No. 10,766,884. The contents of each of the aforementioned documents are incorporated herein by reference in their entirety. PF-07220060 differs from currently approved dual CDK4 / 6 inhibitors in that it exhibits greater selectivity for CDK4 over CDK6. In in vivo models, PF-07220060 is predicted to reduce dose-limiting neutropenia and potentially achieve higher tolerated plasma concentrations than dual CDK4 / 6 inhibitors, and thus may be able to increase inhibition of the CDK4 oncogene in tumors. Summary of the Invention [Problem to be solved by the invention]

[0007] There is a need for appropriate and effective dosing regimens of PF-07220060 as monotherapy and in combination therapy to treat cancer while minimizing adverse events. [Means for solving the problem]

[0008] The present disclosure relates to both single agent and combination therapies for treating cancer comprising the CDK4 inhibitor PF-07220060, or a pharma- ceutically acceptable salt thereof.

[0009] In certain embodiments, the disclosure provides a method of treating cancer comprising orally administering a therapeutically effective amount of PF-07220060, or a pharma- ceutically acceptable salt thereof, to a subject in need of such treatment. In particular, the method comprises administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of PF-07220060 in a total daily dose of about 200 mg to about 1000 mg per day, and in certain embodiments, about 100 mg to about 500 mg twice a day (BID).

[0010] In certain embodiments, the present disclosure provides a method of treating cancer, comprising administering a therapeutically effective amount of PF-07220060, or a pharma- ceutically acceptable salt thereof, and an endocrine therapy to a subject in need of cancer treatment. In embodiments, the endocrine therapy is an aromatase inhibitor, a selective estrogen receptor degrader (SERD), or a selective estrogen receptor modulator (SERM). In embodiments, the endocrine therapy is fulvestrant, tamoxifen, toremifene, anastrozole, exemestane, or letrozole.

[0011] Thus, embodiments herein provide dosing regimens of PF-07220060 as a single agent and combination therapy for treating cancer, which minimizes adverse effects in subjects during treatment. [Brief description of the drawings]

[0012] [Figure 1] FIG. 1 shows PF-07220060 plasma concentration versus nominal time profiles on Day 1 of Cycle 1 after oral administration of PF-07220060 as monotherapy or in combination with letrozole or fulvestrant. [Diagram 2] FIG. 1 shows PF-07220060 plasma concentration versus nominal time profile on Day 15 of Cycle 1 after repeated BID oral administration of PF-07220060 as monotherapy or in combination with letrozole or fulvestrant. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0013] The present disclosure can be more easily understood by referring to the following detailed description of the aspects and embodiments of the present disclosure and the examples contained herein. It should be understood that the terms used herein are only for describing specific embodiments and are not intended to be limiting. It should be further understood that unless specifically defined herein, the technical terms used herein are given their conventional meanings as known in the relevant art.

[0014] Definition: As used herein, the singular forms "a," "an," and "the" include plural references unless otherwise indicated. For example, "a" substituent includes one or more substituents.

[0015] The term "about" means that the value falls within the acceptable standard error of the mean as considered by one of ordinary skill in the art. In some embodiments, the term "about" means within ±10% of the indicated value. For example, a dose of about 400 mg should be understood to mean that the dose may vary between 360 mg and 440 mg.

[0016] The disclosure set forth herein may suitably be practiced in the absence of any element not specifically disclosed herein. Thus, for example, in each instance herein, any of the terms "comprising," "consisting essentially of," and "consisting of" may be replaced with either of the other two terms.

[0017] As used herein, "dose limiting toxicity" (DLT) refers to a dose of PF-07220060 at which further escalation of the dose is contraindicated.

[0018] As used herein, a "measurable lesion" refers to a lesion that can be accurately measured in at least one dimension, a lesion that has a longest diameter of at least twice the slice thickness and at least 10 mm when assessed by CT or MRI (slice thickness 5-8 mm), a lesion that has a longest diameter of at least 20 mm when assessed by chest x-ray, a superficial lesion that has a longest diameter of at least 10 mm when assessed with calipers, or a malignant lymph node that has a short axis of at least 15 mm when assessed by CT.

[0019] As used herein, "maximum tolerated dose" (MTD) refers to the highest dose of PF-07220060 that does not cause unacceptable side effects or intolerable toxicity. The MTD was estimated using the mTPI based on observed DLT rates, with a target DLT rate of 27.5% and an equivalence interval of 22.5-32.5%.

[0020] As used herein, the term "pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient" refers to an ingredient that may be included in the compositions described herein and that is physiologically suitable for pharmaceutical use and does not cause significant adverse effects in the subject.

[0021] As used herein, a "rest period" is the number of days between one full dose of an active agent and the next full dose of an active agent.

[0022] As used herein, the term "week" means seven consecutive days. Thus, a four week period is 28 consecutive days starting on any day of the calendar week.

[0023] As used herein, the term "subject" may be a mammal, which refers to any animal species of the mammalian class. Examples of mammals include humans; non-human primates such as monkeys; laboratory animals such as rats, mice, guinea pigs; domestic animals such as cats, dogs, rabbits, cows, sheep, goats, horses, and pigs; and captive wild animals such as lions and tigers. In some embodiments, the subject is a human. In some embodiments, the subject is a female. In some embodiments, the subject is a male.

[0024] As used herein, the phrase "therapeutically effective amount" for use and / or for treating a subject refers to an amount that, in single or multiple administrations, alone or in combination with one or more other agents, treatments, protocols, or treatment plans, provides a detectable response of any duration (transient, medium-term, or long-term), any measurable or detectable degree, or any duration (e.g., hours, days, months, years, remission, or cure) of a desired outcome or objective or subjective benefit to the subject. Such an amount is typically effective to improve the disease, or one, more, or all adverse effects / symptoms, consequences, or complications of the disease to a measurable degree, although reducing or inhibiting the progression or worsening of the disease, or providing a stable (i.e., non-worsening) state of the disease, is considered a satisfactory outcome. The term "therapeutically effective amount" also refers to an amount of an active agent that is effective to provide a desired therapeutic effect when administered to a subject, for example, to stop the growth or cause shrinkage of a cancerous tumor.

[0025] Determining a therapeutically effective amount is well within the ability of one of ordinary skill in the art. In various embodiments, the dosage can vary within a range depending on the dosage form employed and the route of administration utilized. In some embodiments, the therapeutically effective amount of the compound described herein administered to a subject can depend on factors known to those of ordinary skill in the art, including the biological activity and bioavailability of the compound (e.g., the half-life and stability of the compound in the body), the chemical properties of the compound (e.g., molecular weight, hydrophobicity, and solubility); the route and frequency of administration, and the like. In addition, it will be understood that the specific dose of a pharmaceutical composition comprising a compound described herein can depend on a variety of factors, including the physical condition of the subject (e.g., age, sex, weight), and the medical history of the subject (e.g., medications being taken, health conditions, other diseases or disorders). The exact dose of the pharmaceutical composition administered to a subject can be determined by methods known to those of ordinary skill in the art, such as a pharmacologist or anesthesiologist.

[0026] As used herein, the term "ameliorate" refers to some reduction in the degree, severity, frequency, and / or likelihood of a symptom or clinical sign characteristic of a particular disease. "Symptom" refers to any subjective evidence of a disease or condition in a subject.

[0027] As used herein, "treating" or "treating" cancer and / or cancer-related disease means administering a monotherapy or combination therapy according to the present disclosure to a subject, patient, or individual having or diagnosed with cancer to achieve at least one positive therapeutic effect, such as reducing the number of cancer cells, reducing tumor size, reducing the rate of cancer cell invasion into peripheral organs, or reducing the rate of tumor metastasis or growth, reversing, reducing, inhibiting progression, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition. The term "treatment", as used herein, unless otherwise indicated, refers to the act of treating as defined immediately above for "treating". The term "treating" also includes adjuvant and neoadjuvant treatment of a subject. For the purposes of the present invention, beneficial or desired clinical outcomes include, but are not limited to, one or more of the following: reduced proliferation (or destruction) of neoplastic or cancerous cells; inhibition of metastasis or neoplastic cells; reduction or decrease in tumor size; remission of cancer; reduction of symptoms caused by cancer; improvement of quality of life for people suffering from cancer; reduction of the dose of other drugs required to treat cancer; delay of cancer progression; cure of cancer; overcoming one or more resistance mechanisms of cancer; and / or prolonged survival of cancer patients. Positive therapeutic effects in cancer can be measured in several ways (see, for example, WA Weber, J.Nucl.Med.50:1S-10S (2009)).

[0028] "Tumor" as applied to a subject diagnosed with or suspected of having cancer refers to a malignant or potentially malignant neoplasm or mass of tissue of any size, including primary and secondary neoplasms. A solid tumor is an abnormal growth or mass of tissue that does not usually contain cysts or liquid areas. Examples of solid tumors are sarcomas, carcinomas, and lymphomas. Leukemias (cancers of the blood) generally do not form solid tumors (National Cancer Institute, Cancer Glossary).

[0029] As used herein, the term "combination" or "combination therapy" refers to the administration of two or more therapeutic agents of the combination therapy, either alone or in the form of a pharmaceutical composition or medicament. The combination therapy can be administered sequentially, in parallel, or simultaneously.

[0030] When two or more drugs are administered in combination, the drugs may be administered in the same treatment cycle or using different cycles. In a preferred embodiment, PF-07220060 is administered continuously in a 28-day cycle. Similarly, letrozole is typically administered continuously in a 28-day treatment cycle. Palbociclib is typically administered using an intermittent 28-day treatment cycle, including 21 days of drug administration and 7 days of rest between cycles. Fulvestrant is typically administered intramuscularly on days 1, 15, and 29 of the first treatment cycle, and once a month thereafter.

[0031] Each therapeutic agent of the methods and combination therapies described herein can be administered alone or in a pharmaceutical preparation (also referred to herein as a pharmaceutical composition) comprising the therapeutic agent and one or more pharma- ceutically acceptable carriers, excipients, or diluents in accordance with pharmaceutical practice.

[0032] The term "sequential" or "sequentially" refers to the administration of each therapeutic agent of a combination therapy, either alone or in a pharmaceutical preparation, one after the other, where each therapeutic agent can be administered in any order. Sequential administration can be particularly useful when the therapeutic agents in the combination therapy are in different dosage forms, e.g., when one agent is a tablet and another agent is a sterile liquid, and / or when the agents are administered according to different dosing schedules, e.g., when one agent is administered daily and the second agent is administered less frequently, such as once a week.

[0033] The term "concurrently" refers to the administration of each therapeutic agent in a combination therapy, either alone or in separate pharmaceutical formulations, where the second therapeutic agent is administered immediately after the first therapeutic agent, although the therapeutic agents can be administered in any order. In a preferred embodiment, the therapeutic agents are administered in parallel.

[0034] The term "simultaneous" refers to the administration of each therapeutic agent of the combination therapy in the same pharmaceutical agent, for example, a fixed dose combination containing two or more drugs in a single dosage form.

[0035] A "dosing regimen" refers to a period of administration of one or more drugs, compounds, or compositions, including one or more treatment cycles, where each treatment cycle may involve administering one or more agents at different times, frequencies, or amounts using the same or different routes of administration. Repeated administration or dosing regimens, or adjustments of administration or dosing regimens, may be performed as necessary to achieve a desired therapeutic effect.

[0036] PF-07220060 (Pfizer Inc.) is a selective CDK4 inhibitor currently in Phase I / Ib clinical trials for the treatment of cancer, and has the structure of formula (I):

[0037] [ka]

[0038] Accordingly, certain embodiments of the present disclosure provide therapeutic dosage and dosing regimens that comprise administering to a subject a therapeutically effective amount of PF-07220060.

[0039] PF-07220060 can be present in a pharmaceutical composition that includes a pharma- ceutically acceptable carrier. The therapeutically effective amount of PF-07220060 in the pharmaceutical composition can be from about 200 mg to about 1000 mg, or any therapeutically effective amount disclosed herein.

[0040] In certain embodiments, the therapeutically effective amount of PF-07220060 is from about 200 mg to about 1000 mg per day (i.e., total daily dose), e.g., from about 200 mg to about 500 mg, from about 200 mg to about 450 mg, from about 200 mg to about 400 mg, from about 200 mg to about 350 mg, from about 200 mg to about 300 mg, from about 400 mg to about 950 mg, about 400 mg to about 900 mg, about 400 mg to about 850 mg, about 400 mg to about 800 mg, about 500 mg to about 950 mg, about 500 mg to about 900 mg, about 500 mg to about 850 mg, about 500 mg to about 800 mg, about 600 mg to about 950 mg, about 600 mg to about 900 mg, about 600 mg to about 850 mg, or about 600 mg to about 800 mg.

[0041] In certain embodiments, PF-07220060 is administered at a dose of about 200 mg to about 1000 mg once daily (QD), e.g., about 200 mg to about 500 mg QD, about 200 mg to about 450 mg QD, about 200 mg to about 400 mg QD, about 200 mg to about 350 mg QD, about 200 mg to about 300 mg QD, about 400 mg to about 950 mg QD, about 400 mg to about 900 mg QD, about 40 The dose is about 0 mg to about 850 mg QD, about 400 mg to about 800 mg QD, about 500 mg to about 950 mg QD, about 500 mg to about 900 mg QD, about 500 mg to about 850 mg QD, about 500 mg to about 800 mg QD, about 600 mg to about 950 mg QD, about 600 mg to about 900 mg QD, about 600 mg to about 850 mg QD, or about 600 mg to about 800 mg QD.

[0042] In certain embodiments, a therapeutically effective amount of PF-07220060 is about 100 mg to about 500 mg twice daily (BID), e.g., about 200 mg to about 500 mg BID, about 250 mg to about 500 mg BID, about 300 mg to about 500 mg BID, about 350 mg to about 500 mg BID, about 400 mg to about 500 mg BID, about 100 mg to about 450 mg BID, about 150 mg to about 450 mg BID, about 200 mg to about 500 mg BID, or about 500 mg BID. about 200 mg to about 400 mg BID, about 250 mg to about 400 mg BID, about 300 mg to about 450 mg BID, about 350 mg to about 450 mg BID, about 400 mg to about 450 mg BID, about 100 mg to about 400 mg BID, about 150 mg to about 400 mg BID, about 200 mg to about 400 mg BID, about 250 mg to about 400 mg BID, about 300 mg to about 400 mg BID, and about 350 mg to about 400 mg BID.

[0043] In some embodiments, the subject is administered PF-07220060 at any of the therapeutically effective doses disclosed herein.

[0044] Pharmaceutical compositions containing a therapeutically effective amount of PF-07220060 as described herein can be administered once daily (QD) or twice daily (BID).

[0045] In some embodiments, the subject is administered PF-07220060 at a dose of about 200 mg to about 1000 mg per day, e.g., a daily dose of about 200 mg, about 300 mg, about 400 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, or 1000 mg.

[0046] In some embodiments, PF-07220060 is administered at a dose of about 200 mg QD, about 300 mg QD, about 400 mg QD, about 500 mg QD, about 600 mg QD, about 700 mg QD, about 800 mg QD, about 900 mg QD, or about 1000 mg QD.

[0047] In some embodiments, PF-07220060 is administered at a dose of about 100 mg BID, about 200 mg BID, about 300 mg BID, about 400 mg BID, or about 500 mg BID.

[0048] The amount of PF-07220060 administered may be increased or decreased based on the subject's weight, age, health, sex, or medical condition. One of skill in the art would be able to determine the appropriate dose for a subject based on this disclosure.

[0049] PF-07220060 can be administered in treatment cycles, with or without rest periods between treatment cycles. Treatment cycles can be for a period of about 7 days, about 14 days, about 21 days, about 28 days, about 35 days, etc., or any number of days in between. The rest period can be for one day, several days (e.g., 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, etc.), one week, several weeks (e.g., 2 weeks, 3 weeks, etc.), or any number of days in between (e.g., 1 week and 3 days). In some embodiments, PF-07220060 is administered continuously without any rest periods in between (i.e., continuous treatment until completion). In some embodiments, PF-07220060 is administered in treatment cycles (e.g., about 28 days) with or without rest periods. In some embodiments, PF-07220060 is administered for about 28 days with about one week rest period. PF-07220060 may be administered for at least about 7 days, about 14 days, about 21 days, about 28 days, about 2 months, about 3 months, about 12 months, about 24 months, and longer.

[0050] The pharmaceutical compositions may be administered with or without food.

[0051] Pharmaceutical compositions can be administered by one or more routes as deemed appropriate by those skilled in the art and depending on the dosage form. Drug formulations are described in Remington's Pharmaceutical Sciences, 18th Edition, (1995) Mack Publishing Co., Easton, Pennsylvania. Other examples of drug formulations can be found in Liberman, HA and Lachman, L., eds., Pharmaceutical Dosage Forms, Marcel Decker, vol. 3, 2nd Edition, New York, New York. When the compound is administered orally, it can be formulated as pills, capsules, tablets, etc. with pharmaceutically acceptable carriers, lubricants, or excipients.

[0052] The pharmaceutical composition may be in one or more dosage forms (eg, capsule, liquid, tablet, powder).

[0053] In some embodiments, the pharmaceutical compositions may be administered in an immediate or modified release formulation.

[0054] "Immediate release" or "IR" broadly refers to an oral dosage form formulated to release an API immediately after oral administration. In IR formulations, no attempt is made to purposefully modify the rate of drug release.

[0055] Treatment Methods and Uses In certain embodiments, the disclosure provides a method of treating cancer in a subject in need of such treatment, comprising administering to the subject a therapeutically effective amount of PF-07220060 as described herein.

[0056] In certain embodiments, the disclosure also provides a method of treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of PF-07220060 and an endocrine therapy agent as described herein.

[0057] In certain embodiments, the disclosure provides for the use of PF-07220060 in the manufacture of a medicament for use in treating cancer in a subject in need thereof, wherein the medicament is administered in a therapeutically effective unit dose of PF-07220060 as described herein.

[0058] In certain embodiments, the disclosure provides for the use of PF-07220060 in combination with endocrine therapy in the manufacture of a medicament for use in treating cancer in a subject in need thereof, wherein the medicament is administered in a therapeutically effective unit dose of PF-07220060 as described herein.

[0059] In certain embodiments, the disclosure provides a pharmaceutical agent comprising a therapeutically effective amount of PF-07220060 as described herein for use in treating cancer in a subject in need thereof.

[0060] In embodiments, the disclosure provides a pharmaceutical product comprising a therapeutically effective amount of PF-07220060 as described herein and an endocrine therapy agent for use in treating cancer in a subject in need thereof.

[0061] In certain embodiments of each of the methods, medicaments, combinations and uses described herein, PF-07220060 is administered continuously (ie, daily).

[0062] In certain embodiments, the methods disclosed herein comprise administering PF-07220060 to a subject suffering from a cancer mediated by CDK4. In some embodiments, the cancer is characterized by amplification or overexpression of CDK4 and / or CCND1. In one embodiment, the cancer is characterized by amplification or overexpression of CDK4. In one embodiment, the cancer is characterized by amplification of the CCND1 gene or overexpression of cyclin D1.

[0063] In certain embodiments, the methods disclosed herein comprise administering PF-07220060 to a subject suffering from a cancer selected from breast cancer, ovarian cancer, fallopian tube cancer, primary peritoneal cancer (PPC), bladder cancer, uterine cancer, prostate cancer, lung cancer (including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), squamous cell carcinoma, or adenocarcinoma), esophageal cancer, head and neck cancer (including head and neck squamous cell carcinoma (HNSCC)), colorectal cancer (CRC), kidney cancer (including renal cell carcinoma (RCC)), liver cancer (including hepatocellular carcinoma (HCC)), pancreatic cancer, stomach (i.e., gastric) cancer, endometrial cancer, liposarcoma, and thyroid cancer. In further embodiments of the methods provided herein, the cancer is selected from the group consisting of breast cancer, ovarian cancer, bladder cancer, uterine cancer, prostate cancer, lung cancer, esophageal cancer, liver cancer, pancreatic cancer, gastric cancer, or a combination thereof.

[0064] In some embodiments, the cancer is an advanced or metastatic solid tumor.

[0065] In some embodiments, the cancer is NSCLC. In some embodiments, the cancer is adenocarcinoma of NSCLC. In some embodiments, the cancer is prostate cancer. In some embodiments, the cancer is colorectal cancer. In some embodiments, the cancer is liposarcoma.

[0066] In some embodiments, the cancer is breast cancer. In some embodiments, the breast cancer is advanced or metastatic breast cancer. In some embodiments, the breast cancer is locally advanced. In some embodiments, the breast cancer is metastatic breast cancer. In some embodiments, the breast cancer is hormone receptor positive (HR+), i.e., the breast cancer is estrogen receptor positive (ER+) and / or progesterone receptor positive (PR+). In some embodiments, the breast cancer is hormone receptor negative (HR-), i.e., the breast cancer is estrogen receptor negative (ER-) and progesterone receptor negative (PR-). In some embodiments, the breast cancer is human epidermal growth factor receptor 2 negative (HER2-). In some embodiments, the breast cancer is human epidermal growth factor receptor 2 positive (HER2+). In some embodiments, the breast cancer is HR+ / HER2- breast cancer. In some embodiments, the breast cancer is HR- / HER2+ breast cancer. In some embodiments, the breast cancer is ER+ / HR+. In some embodiments, the breast cancer is ER+ / HER2-. In some embodiments, the breast cancer is triple-negative breast cancer (TNBC), i.e., the breast cancer is ER-, PR-, and HER2-.

[0067] In some embodiments, the breast cancer is endocrine therapy-resistant breast cancer, trastuzumab or pertuzumab-resistant breast cancer, or breast cancer that shows primary or acquired resistance to CDK4 / CDK6 inhibition.In some embodiments, the breast cancer shows resistance to treatment with standard therapeutic agents, for example, the breast cancer may show primary or acquired resistance to endocrine therapy, HER2-targeting agents (e.g., tamoxifen, trastuzumab emtansine, fam-trastuzumab deruxtecan, pertuzumab, lapatinib, neratinib, or tucatinib), or CDK4 / 6 inhibitors.In some embodiments, the subject is refractory to endocrine therapy.

[0068] In some embodiments, the breast cancer is refractory or resistant to, or has progressed during, treatment with an anti-neoplastic chemotherapeutic agent, such as a platinum agent, a taxane, an anthracycline, or an antimetabolite.

[0069] In some embodiments, the breast cancer has progressed during or within 12 months of completing adjuvant aromatase inhibitor therapy, hi some embodiments, the breast cancer has progressed during or within 12 months of completing adjuvant tamoxifen therapy.

[0070] In some embodiments, PF-07220060 is administered as a first-line therapy. In other embodiments, PF-07220060 is administered as a second (or subsequent) line therapy. In some embodiments, PF-07220060 is administered as a second (or subsequent) line therapy after treatment with an endocrine therapy and / or CDK4 / CDK6 inhibitor. In some embodiments, PF-07220060 is administered as a second (or subsequent) line therapy after treatment with an endocrine therapy, such as an aromatase inhibitor; a selective estrogen receptor modulator (SERM), e.g., tamoxifen; or a selective estrogen receptor degrader / downregulator (SERD). In some embodiments, PF-07220060 is administered as a second (or subsequent) line therapy after treatment with one or more chemotherapy regimens. In some embodiments, PF-07220060 is administered as a second (or subsequent) line therapy after treatment with a HER2-targeted agent.

[0071] In certain embodiments, the methods disclosed herein further comprise administering to the subject a therapeutically effective amount of PF-07220060 and an endocrine therapy. An "endocrine therapy" is a biological (large molecule) or chemical (small molecule) compound useful in the treatment of cancer, regardless of mechanism of action.

[0072] In some embodiments, the endocrine therapy is an aromatase inhibitor, an androgen receptor inhibitor, a selective estrogen receptor degrader (SERD), or a selective estrogen receptor modulator (SERM). In some embodiments, the endocrine therapy is an androgen receptor inhibitor. In some embodiments, the endocrine therapy is an aromatase inhibitor. In some such embodiments, the aromatase inhibitor is selected from the group consisting of letrozole, anastrozole, and exemestane. In one embodiment, the aromatase inhibitor is letrozole. In some embodiments, the endocrine therapy is a SERD. In some such embodiments, the SERD is selected from the group consisting of fulvestrant, elacestrant (RAD-1901, Radius Health / Menarini), amsenestrant (SAR439859, Sanofi), diledestrant (GDC9545, Roche), RG6171 (Roche), camizestrant (AZD9833, AstraZeneca), AZD9496 (AstraZeneca), lindestrant (G1 Therapeutics), ZN-c5 (Zentalis), LSZ102 (Novartis), D-0502 (Inventisbio), LY3484356 (Eli Lilly), and SHR9549 (Jiansu Hengrui Medicine). In some embodiments, the SERD is fulvestrant. In some embodiments, the endocrine therapy is a SERM. In some such embodiments, the SERM is selected from the group consisting of tamoxifen, raloxifene, toremifene, lasofoxifene, bazedoxifene, and afimoxifene.In some such embodiments, the SERM is tamoxifen or raloxifene.In preferred embodiments, the endocrine therapy agent is letrozole or fulvestrant.

[0073] Endocrine therapy agents may be administered according to the standard of care per the package insert or may be provided by a healthcare professional. The term "package insert" refers to instructions customarily included in commercial packaging of a therapeutic product and which contain information about the indications, usage, dosage, administration, contraindications, and / or warnings for the use of such therapeutic product.

[0074] In certain embodiments, the endocrine therapy is administered to the subject during the course of treatment with PF-07220060. In certain embodiments, the first dose of the endocrine therapy is administered prior to administration of the first dose of PF-07220060. In certain embodiments, the first dose of the endocrine therapy is administered on the same day as administration of the first dose of PF-07220060. In certain embodiments, the first dose of the endocrine therapy is administered after initiation of treatment with PF-07220060.

[0075] In certain embodiments, prior to administering PF-07220060 to the subject, the subject has previously been treated with one or more lines of endocrine therapy.

[0076] In certain embodiments, prior to administering PF-07220060 to the subject, the subject has been previously treated with chemotherapy, radiation therapy, and / or surgical resection.

[0077] In certain embodiments, prior to administering PF-07220060 to the subject, the subject has been previously treated with a CDK4 / 6 inhibitor.

[0078] In some embodiments, the treatment results in a complete response (CR), partial response (PR), or stable disease (SD) in the subject.

[0079] Treatment outcomes and tumor response assessments This therapy may result in complete response (CR), partial response (PR), progressive disease (PD), or stable disease (SD) in patients. Bioimaging can be used to assess the response level to treatment. Cytological and histological diagnosis can also be used if necessary (e.g., to identify the location of residual disease). In some embodiments, various response levels can be evaluated according to Table 1 below.

[0080] [Table 1]

[0081] The present disclosure provides several exemplary embodiments, non-limiting exemplary embodiments of the present disclosure are set forth below.

[0082] Embodiment 1. A method of treating cancer comprising orally administering a therapeutically effective amount of PF-07220060, or a pharma- ceutically acceptable salt thereof, to a subject in need of such treatment, wherein the therapeutically effective amount is about 100 mg to about 500 mg twice daily (BID).

[0083] Embodiment 2. The method of embodiment 1, wherein the therapeutically effective amount is about 300 mg to about 500 mg BID.

[0084] Embodiment 3. The method of embodiment 1 or 2, wherein the therapeutically effective amount is about 300 mg BID.

[0085] Embodiment 4. The method of embodiment 1 or 2, wherein the therapeutically effective amount is about 400 mg BID.

[0086] Embodiment 5. The method of any one of embodiments 1 to 4, wherein PF-07220060 is administered continuously.

[0087] Embodiment 6. The method of any one of embodiments 1 to 5, wherein PF-07220060 is administered in the form of a tablet or capsule.

[0088] Embodiment 7. A method of treating cancer comprising administering to a subject in need of treatment a therapeutically effective amount of a pharmaceutical composition comprising PF-07220060 and an endocrine therapy agent, wherein the therapeutically effective amount of PF-07220060 is from about 100 mg to about 500 mg BID.

[0089] Embodiment 8. The method of embodiment 7, wherein the endocrine therapy is an aromatase inhibitor, an androgen receptor inhibitor, a selective estrogen receptor degrader (SERD), or a selective estrogen receptor modulator (SERM).

[0090] Embodiment 9. The method of embodiment 7, wherein the endocrine therapy is selected from the group consisting of letrozole, anastrozole, exemestane, fulvestrant, elacestrant, amsenestrant, diredestrant, RG6171, camizestrant, AZD9496, lindestrant, ZN-c5, LSZ102, D-0502, LY3484356, SHR9549, tamoxifen, raloxifene, toremifene, lasofoxifene, bazedoxifene, and afimoxifene.

[0091] Embodiment 10. The method of embodiment 7, wherein the endocrine therapy is letrozole or fulvestrant.

[0092] Embodiment 11. The method of any one of embodiments 7 to 10, wherein the subject is administered an endocrine therapy agent followed by administration of PF-07220060.

[0093] Embodiment 12. The method of embodiment 1 or 7, wherein the subject has previously been treated with chemotherapy, radiation therapy, and / or surgical resection.

[0094] Embodiment 13. The method of embodiment 1 or 7, wherein the subject has previously been treated with a CDK4 / 6 inhibitor.

[0095] Embodiment 14. The method of embodiment 1 or 7, wherein the subject has been previously treated with an endocrine therapy agent.

[0096] Embodiment 15. The method of embodiment 1 or 13, wherein the subject is a mammal.

[0097] Embodiment 16. The method of any one of embodiments 1 to 15, wherein the subject is afflicted with breast cancer, ovarian cancer, fallopian tube cancer, primary peritoneal cancer, bladder cancer, uterine cancer, prostate cancer, lung cancer, esophageal cancer, head and neck cancer, colorectal cancer, kidney cancer, liver cancer, pancreatic cancer, gastric cancer, and thyroid cancer.

[0098] Embodiment 17. The method of any one of embodiments 1 to 16, wherein the cancer is breast cancer selected from any one or more of hormone receptor positive (HR+), hormone receptor negative (HR-), human epidermal growth factor receptor 2 negative (HER2-), human epidermal growth factor receptor 2 positive (HER2+), HR+ / HER2-, ER- / HR+, ER+ / HER2-, and triple negative breast cancer (TNBC).

[0099] Embodiment 18. The method of any one of embodiments 1 to 16, wherein the cancer is NSCLC, prostate cancer, colorectal cancer, liposarcoma, or a tumor characterized by amplification or overexpression of CDK4 and / or CCND1.

[0100] Embodiment 19. Use of PF-07220060 in the manufacture of a medicament for use in treating cancer in a subject in need thereof, wherein the medicament is administered in an amount of about 100 mg to about 500 mg BID as a therapeutically effective unit dose of PF-07220060.

[0101] Embodiment 20. Use of PF-07220060 and an endocrine therapy agent in the manufacture of a medicament for use in treating cancer in a subject in need thereof, wherein the medicament is administered in an amount of about 100 mg to about 500 mg BID as a therapeutically effective unit dose of PF-07220060.

[0102] Embodiment 21. A pharmaceutical product comprising a therapeutically effective amount of PF-07220060 for use in treating cancer in a subject in need thereof, wherein the therapeutically effective amount is from about 100 mg to about 500 mg BID.

[0103] Embodiment 22. A pharmaceutical product comprising a therapeutically effective amount of PF-07220060 and an endocrine therapy agent for use in treating cancer in a subject in need thereof, wherein the therapeutically effective amount is from about 100 mg to about 500 mg BID. EXAMPLES

[0104] The following examples are merely illustrative of the disclosure and should not be construed as limiting the scope of the invention in any way, as these and other equivalents will become apparent to those of skill in the art in light of this disclosure and the appended claims.

[0105] Example 1 Inhibition of multicellular tumor spheroid growth by single agent PF-07220060 and in combination with fulvestrant The objective of this example was to evaluate the effect of PF-07220060 in combination with endocrine therapy in inhibiting multicellular tumor spheroid growth (SGI).

[0106] To model human tumor characteristics and cellular behavior, the activity of PF-07220060 was evaluated in 3D MCTS models of HR+ breast and AR+ prostate cancer after treatment with PF-07220060 as a single agent and in combination with fulvestrant in spheroids: 1) HR+, HER2-T47D breast cancer spheroids, 2) HR+, HER2+BT474 breast cancer spheroids; 3) BT474 spheroids, and 4) AR+ prostate carcinoma cell line (LNCaP) prostate cancer spheroids. Spheroids were treated with increasing concentrations of PF-07220060 (100, 300, or 1000 nM) and compared to palbociclib at a clinically relevant concentration of 30 nM. Single-agent PF-07220060 dose-dependently inhibited spheroid growth, with the highest efficacy (86% SGI over the treatment period at 1000 nM) in the T47D breast cancer spheroid model (Table 1). Combining 100 nM PF-07220060 with 1 nM fulvestrant in T47D cells increased SGI to 96% compared to either single agent alone (57-67% SGI with 100 nM PF-07220060 or 79% SGI with fulvestrant) (Table 1). BT474 spheroids were relatively insensitive to PF-07220060, with an SGI of 52% at 1000 nM.

[0107] PF-07220060 demonstrated dose-dependent inhibition of LNCaP prostate cancer spheroid growth, reaching an SGI of 53% at 1000 nM (Table 1).

[0108] In summary, these data support the use of PF-07220060 in combination with endocrine therapy in HR+, HER2- breast cancer. There are additive or synergistic benefits with PF-07220060 combinations across multiple tumor types. PF-07220060 inhibits spheroid growth in a dose-dependent manner when used as a single agent, with the highest activity seen in HR+, HER2- breast cancer spheroid models.

[0109] [Table 2]

[0110] Example 2 Clinical Trial Protocol An ongoing open-label, non-randomized, dose-ranging Phase 1 / 1b study investigating the safety, tolerability, PK, and PD of PF-07220060 administered as a single agent and in combination with endocrine therapy.

[0111] research design In Part 1A, single ascending doses of PF-07220060 alone will be administered sequentially starting at a dose of 100 mg BID to determine the maximum tolerated dose (MTD) of PF-07220060 as monotherapy and / or to select the recommended Phase 2 dose (RP2D).

[0112] In Part 1B and Part 1C, PF-07220060 will be administered in combination with endocrine therapy (letrozole or fulvestrant) to identify the MTD and / or select the RP2D of PF-07220060 in combination with each endocrine therapy agent.

[0113] Part 1D will evaluate the effect of food on the PK of PF-07220060 at or below the MTD of monotherapy. In Part 1D, participants will receive PF-07220060 as a single agent at or below the MTD of monotherapy on the preceding 7 days, then continuously from Day 1, to evaluate the effect of food.

[0114] In Part 1E, we will evaluate potential drug-drug interactions (DDIs) between PF-07220060 and midazolam administered at or below the monotherapy MTD established in Part 1A.

[0115] Part 2B is an expansion cohort of PF-07220060 in combination with letrozole in patients with HR+ / HER2-negative advanced or metastatic breast cancer (mBC) who have not previously received systemic anti-cancer therapy for progressive disease.

[0116] Part 2C is an expansion cohort of PF-07220060 in combination with fulvestrant (with or without goserelin) in patients with HR-positive / HER2-negative advanced or mBC whose disease has progressed on prior therapy.

[0117] Study entry is defined as day 1 of dosing. All cycles are 28 days in length. Evaluation of alternative dosing regimens (e.g., QD) may be considered during the course of dose escalation or after determining the MTD / RP2D of the BID regimen based on new and available preliminary clinical data, including safety / tolerability, laboratory testing, PK, and PD findings. Dosing schedules of intermittently administered PF-07220060 (e.g., 3 weeks on, 1 week off) may also be evaluated if indicated based on new clinical data.

[0118] Participants who experience toxicity, including DLTs, may be managed by dose modification or discontinuation of treatment. The proposed dose, schedule, and PK time points may be modified during the study based on emerging safety and PK data.

[0119] The length of time the study will take may vary depending on any toxicities observed and the potential benefit each individual participant derives. Each participant is estimated to continue approximately 6-8 cycles of treatment, making the total study duration approximately 24-32 weeks. The actual duration may be longer if participants benefit from the study treatment.

[0120] Based on the evolution of the PK, PD, and safety profile evaluated in Part 1A, the starting dose of PF-07220060 in Part 1B and Part 1C may begin at the MTD or at a dose level determined to be safe by Bayesian logistic regression model (BLRM) that meets the Extension with Overdose Control (EWOC) criteria in Part 1A before reaching the MTD. (Rogatko, A. et al., Translation of Innovative Designs Into Phase Trials, J. Clin. Oncol., 25(31), 4982-6, 2007). The use of EWOC principles limits the risk of treating participants at doses above the MTD. Additionally, multiple dosing regimens (e.g., different doses, dosing frequencies) of PF-07220060 may be explored in Part 1B and Part 1C.

[0121] Study population The eligibility criteria are designed to select participants who are deemed suitable to participate in the study. The inclusion criteria for patient selection are as follows: All participants - histologically or cytologically proven locally advanced or metastatic solid tumors that were unresectable or could not be irradiated with curative intent.

[0122] Part 1 Disease Requirements Part 1B and Part 1C: · Refractory HR positive / HER2 negative (2L+ with pre-CDK4 / 6) breast cancer. Part 1A, Part 1D, and Part 1E: Refractory HR+ / HER2+ breast cancer. Non-breast tumors: NSCLC, prostate cancer, CRC, liposarcoma, or tumors with previously confirmed CDK4 or CCND1 amplification by local standard testing.

[0123] Part 2 Disease Requirements Part 2B and Part 2C: HR positive / HER2 negative breast cancer Participants who are: Postmenopausal women, as defined by at least one of the following criteria: Age 60 or older; · Age < 60 years, cessation of regular menses for at least 12 consecutive months without other pathological or physiological causes, and serum estradiol and follicle-stimulating hormone (FSH) levels within the laboratory reference range for postmenopausal women; · Bilateral oophorectomy documented; · Medically confirmed ovarian failure. or In Part 2C: Premenopausal / perimenopausal, i.e. not meeting the postmenopausal criteria. · Pre- / peri-menopausal women may also be enrolled if they are amenable to treatment with the luteinizing hormone releasing hormone (LHRH) agonist goserelin. Participants must have begun treatment with goserelin or an alternative LHRH agonist at least 4 weeks prior to enrollment. If participants are receiving an alternative LHRH agonist prior to study entry, it is recommended that they be switched to goserelin for the duration of the study. However, other LHRH antagonists, such as leuprolide, are acceptable.

[0124] Lesion requirements: In Part 1: Participants must have evaluable lesions (including only skin or bone lesions). In Part 2B and Part 2C: Participants must have measurable disease defined according to RECIST (Response Evaluation Criteria in Solid Tumors) version 1.1 (Eisenhauer et al., European Journal of Cancer, 2009, 45(2):228-47). Tumor lesions previously irradiated or treated locally will be considered measurable only if progression at the treated site after completion of treatment has been clearly documented.

[0125] Pre-systemic treatment: In Part 1: HR positive / HER2 negative breast cancer (Part 1A / Part 1B / Part 1C / Part 1D / Part 1E). Participants should have received: At least one line of standard of care (SOC) including CDK4 / 6 inhibitor therapy for advanced or metastatic disease, or if a CDK4 / 6 inhibitor is available but in the investigator's opinion is not appropriate, the participant may be enrolled if a satisfactory clinical justification is provided by the investigator and approved by the sponsor; or At least one line of anti-endocrine therapy for advanced or metastatic disease in countries where CDK4 / 6 inhibitors are not approved or reimbursed. Pre-chemotherapy for progressive disease is permitted in both of the following cases: HR-positive / HER2-positive breast cancer (Part 1A / Part 1D): Participants should have received at least one prior approved HER2-targeted therapy. Tumors other than breast cancer (Part 1A / Part 1D): Tumors that are refractory to at least two lines of standard systemic therapy for progressive or recurrent disease or for which no standard therapy is available. In Part 2: Part 2B: Participants who have not previously received systemic anticancer therapy for advanced / metastatic breast cancer. Part 2C: Progression during or within 12 months of completion of adjuvant therapy with an aromatase inhibitor if postmenopausal or tamoxifen if premenopausal or perimenopausal; or Progression on or within 1 month of completing prior aromatase inhibitor therapy for advanced / metastatic breast cancer if postmenopausal or prior endocrine therapy for advanced / metastatic breast cancer if premenopausal or perimenopausal. · In addition to endocrine therapy, one line of prior chemotherapy for advanced / metastatic disease is permitted.

[0126] Recruitment criteria The inclusion criteria for the two parts of the study were as follows: 1. Participants in both Part 1 and Part 2 (excluding Part 2B) must be refractory or intolerant to existing therapies known to provide clinical benefit for their condition. 2. Participants are 18 years of age or older. 3.Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 4. Adequate bone marrow function as evidenced by: ANC≧1,500 / mm 3 or ≥ 1.5 × 10 9 / L; b. Platelets ≧100,000 / mm 3 or ≥ 100 × 10 9 / L; Hemoglobin ≥ 9 g / dL. Limited transfusions to achieve this level are permitted after consultation with the Sponsor's medical monitor. There should be no recent (approximately 3 months) or chronic need for transfusions. 5. Adequate renal function defined as: Part 1 estimated creatinine clearance ≥ 50 mL / min calculated using the institution's standard method. In equivocal cases, a 24-hour urine test may be used to more precisely estimate creatinine clearance. 6. Adequate liver function as evidenced by: a. Total serum bilirubin ≤ 1.5 × ULN, unless the participant has documented Gilbert's syndrome (in which case total serum bilirubin ≤ 3.0 × ULN is permitted); b. AST and ALT ≤ 2.5 × ULN; ≤ 5.0 × ULN if tumor-related liver damage is present; c.ALKP ≤ 2.5 × ULN (≤ 5.0 × ULN for bone or liver metastases).

[0127] Exclusion criteria Participants will be excluded from the study if they meet any of the following criteria: 1. In Part 1D: Participants who have undergone a gastrectomy or have a 10-hour overnight fast (water allowed) or dietary or other restrictions that prevent intake of high-fat, high-calorie foods. 2. In Part 2B: Disease recurrence during or within 12 months after completion of prior neoadjuvant or adjuvant treatment with a nonsteroidal aromatase inhibitor (i.e., anastrozole or letrozole) or prior treatment with any CDK4 / 6 inhibitor. 3. In Part 2C: Prior treatment with any CDK inhibitor, or fulvestrant, or everolimus, or any agent with a mechanism of action that inhibits the PI3K-mTOR pathway. 4. Known active, uncontrolled or symptomatic CNS metastases, carcinomatous meningitis, or leptomeningeal disease as indicated by clinical symptoms, cerebral edema, and / or progressive growth. Participants with a history of CNS metastases or spinal cord compression are eligible if they have received definitive treatment (e.g., radiation therapy, stereotactic surgery) and are clinically stable off anticonvulsants and steroids for at least 4 weeks prior to enrollment, and have no evidence of progression at the time of study enrollment. 5. Participants with progressive / metastatic, symptomatic, visceral metastases and at risk for short-term life-threatening complications (including participants with uncontrolled massive effusion [pleural, pericardial, peritoneal], pulmonary lymphangitis, and >50% liver impairment). 6.Any other active malignancy, except adequately treated basal or squamous cell skin cancer or carcinoma in situ, within 3 years prior to enrollment. 7. Major surgery within 4 weeks prior to study entry. 8. Curative radiation therapy within 4 weeks prior to study entry. Any palliative radiation therapy must be completed within 7 days prior to Day 1 of study intervention administration. 9. Within 2 weeks (or 5 half-lives, whichever is shorter) of most recent anti-cancer treatment, except if the most recent anti-cancer treatment included an antibody-based agent (approved or investigational), 4 weeks (or 5 half-lives, whichever is shorter) must elapse before receiving any study intervention. 10. Participants in Part 1C who received fulvestrant as part of their most recent prior therapy are eligible. 11. Previously received high-dose chemotherapy requiring stem cell rescue. 12. Active and clinically significant bacterial, fungal, or viral infection, including but not limited to HBV, HCV, known HIV or AIDS related disease. 13. A baseline 12-lead ECG showing clinically significant abnormalities that may affect the participant's safety or interpretation of the study results (e.g., baseline QTc interval >470 ms, complete LBBB, signs of acute or indeterminate-age myocardial infarction, ST-T interval changes suggestive of active myocardial ischemia, second- or third-degree AV block, or severe bradyarrhythmias or tachyarrhythmias). If the baseline uncorrected QT interval is >470 ms, this interval should be rate-corrected using the Fridericia method, and the resulting QTcF should be used for decision-making and reporting. If the QTc is >470 ms or the QRS is >120 ms, the ECG should be repeated two more times, and the average of the three QTc or QRS values ​​should be used to determine participant eligibility. Computer-interpreted ECGs should be reviewed by a physician experienced in reading ECGs before excluding participants. Cases must be discussed in detail with the sponsor's medical monitor to determine eligibility. 14. Any of the following in the past 6 months: myocardial infarction, congenital long QT syndrome, polymorphic ventricular tachycardia, arrhythmias (including sustained ventricular tachyarrhythmias and ventricular fibrillation), serious conduction system abnormalities (e.g., bifascicular block (defined as right and left anterior or left posterior bundle branch hemiblock), third-degree AV block), unstable angina, coronary artery / peripheral artery bypass graft, symptomatic CHF, New York Heart Association class III or IV, cerebrovascular accident, transient ischemic attack, or symptomatic pulmonary embolism; deep vein thrombosis; arterial occlusive disease; ongoing arrhythmia of NCI CTCAE grade 2 or greater, uncontrolled atrial fibrillation of any grade, or QTcF interval >470 milliseconds at screening. 15. Blood pressure that cannot be controlled (>150 / 100 mmHg despite optimal medical therapy). 16. Therapeutic doses of anticoagulant therapy are prohibited (prophylactic doses of anticoagulants are permitted). 17. Known coagulation abnormalities such as bleeding diathesis. 18. Known or suspected hypersensitivity to the active ingredients / excipients of PF-07220060, letrozole, fulvestrant, enzalutamide, and / or goserelin (or equivalent agents to induce chemical menopause / chemical castration). 19. Active inflammatory GI disease, known diverticular disease, or previous gastrectomy or lap-band surgery. GI dysfunction or disease that may significantly alter the absorption of PF-07220060, such as history of GI surgery that may result in intestinal blindness and clinically significant gastroparesis, short bowel syndrome, unresolved nausea, vomiting, active inflammatory bowel disease, or diarrhea of ​​CTCAE grade >1. 20.Currently using medications that have a risk of QTc prolongation. 21. Treatment with strong and moderate CYP3A4 / 5 inhibitors or UGT2B7 inhibitors, including administration within 5 half-lives of the CYP3A4 / 5 inhibitor or UGT2B7 inhibitor, whichever is longer, prior to the first dose of the study intervention. 22. Treatment with a proton pump inhibitor (e.g., dexlansoprazole, esmerpraole, lansoprazole, omeprazole, pantoprazole, rabeprazole) within 7 days prior to the first dose of the study intervention. 23. Any other medical or psychiatric condition, including recent (within the past year) or current suicidal thoughts / behavior or laboratory abnormalities, that may place study participation at increased risk or that, in the investigator's judgment, may render the participant unsuitable for the study. 24. Pregnant or breastfeeding.

[0128] Example 3 Clinical trial results The Phase 1 / 1b PF-07220060 clinical trial is currently ongoing. As of September 2, 2022, a total of 66 participants (43 women and 23 men) have been treated with PF-07220060 in Part 1A, Part 1B, Part 1C, and Part 1D. The mean age is 61.4 years (range 36-82 years), and this population includes participants with HR+HER2- advanced or mBC, as well as other tumors that may expand in a CDK4-dependent manner, including adenocarcinoma of NSCLC, prostate cancer, CRC, liposarcoma, and tumors with previously confirmed CDK4 or CCND1 amplification according to local standard testing. Demographic data for these 66 participants are shown in Table 2.

[0129] [Table 3-1]

[0130] [Table 3-2]

[0131] Patient population An overview of the patient population in each part of the study is provided in Table 3.

[0132] [Table 4]

[0133] Part 1A - Dose escalation of PF-07220060 alone The objective of Part 1A was to investigate the safety and tolerability of dose escalation of PF-07220060 as a single agent in sequential dose escalation cohorts in women and men of any menopausal status with HR-positive, HER2-negative or HR-positive, HER2-positive, advanced or mBC that has progressed after at least one standard of care (i.e., 2L or later), as well as participants with other solid tumors, e.g., adenocarcinoma of NSCLC, prostate cancer, colorectal cancer, liposarcoma, and tumors with previous CDK4 or CCND1 amplification according to local standard testing. Patients with progressive or metastatic HR-positive mBC could receive additional endocrine therapy (either letrozole or fulvestrant) after at least two cycles of PF-07220060 monotherapy, under certain criteria.

[0134] In Part 1A, single ascending doses of PF-07220060 alone will be administered sequentially starting at a dose of 100 mg BID to determine the MTD and / or select the RP2D of PF-07220060 as monotherapy. Administration will continue in sequential dose-escalation cohorts until the MTD / RP2D can be estimated.

[0135] Thirty-four participants (n=34) were treated with single-agent PF-07220060 at 100 mg (n=3), 200 mg (n=8), 300 mg (n=10), 400 mg (n=9), and 500 mg (n=4) BID in Part 1A (five dose cohorts).

[0136] Part 1B and Part 1C - Dose-finding of PF-07220060 in combination with endocrine therapy The objectives of Parts 1B and 1C were to determine the MTD / RP2D of PF-07220060 when administered in combination with letrozole (Part 1B) or fulvestrant (Part 1C), respectively, in women and men of any menopausal status with HR-positive, HER2-negative advanced or mBC in the 2L+ setting.

[0137] In Part 1B, participants received the approved dose of letrozole 2.5 mg QD administered continuously with PF-07220060. Thirteen participants (n=13) received treatment with PF-07220060 at 300 mg (n=6) and 400 mg (n=7) BID in combination with letrozole in Part 1B (two dose cohorts).

[0138] In Part 1C, participants received two intramuscular (IM) injections of fulvestrant (250 mg each) prior to oral administration of PF-07220060. Fulvestrant was administered at-site by qualified healthcare professionals on days 1 and 15 of cycle 1 and on day 1 (± 1–5 days depending on cycle number) of each subsequent 28-day cycle. Thirteen participants (n=13) were treated with PF-07220060 at 300 mg (n=6) and 400 mg (n=7) BID in combination with fulvestrant in Part 1B (two dose cohorts).

[0139] Part 1D - Effect of food on PF-07220060 The objective of Part 1D was to evaluate the effect of food on the pharmacokinetics (PK) of a single dose of PF-07220060 alone in participants.

[0140] Six participants (n=6) were treated with single-agent PF-07220060 400 mg BID in the morning under "fed" conditions on Day 7 prior to Cycle 1 and "fasted" conditions on Day 1 of Cycle 1. To assess the effect of food, participants' PF-07220060 plasma concentration-time data were compared on Day 7 prior to Cycle 1 and Day 1 of Cycle 1. Natural log-transformed AUC and C max Values ​​were analyzed using an analysis of variance model and treatment as a fixed effect. The model provided estimates of the mean difference (fed-fasted) and corresponding 90% CI. The mean difference and the 90% CI for the difference were exponentiated to provide estimates of the geometric mean ratio (fed / fasted) and the 90% CI for the ratio.

[0141] Part 1E – Midazolam Drug-Drug Interactions The objective of Part 1E is to evaluate the effect of repeat dosing of PF-07220060 at the monotherapy MTD on the PK of oral midazolam in participants with advanced solid tumors. In Part 1E, participants will receive oral midazolam 2 mg alone on day 1 prior to cycle 1 and with PF-07220060 on day 15 of cycle 1. Midazolam will be administered only twice.

[0142] Part 2B and Part 2C - Dose expansion of PF-07220060 in combination with endocrine therapy The objective of Part 2B is to evaluate the tolerability, safety, and preliminary antitumor activity of PF-07220060 in combination with letrozole. Part 2B is a dose expansion of PF-07220060 in combination with letrozole at the dose specified in Part 1B in participants with HR-positive, HER2-negative advanced / metastatic breast cancer who have not received any prior systemic anticancer therapy for their progressive disease. In Part 2B, participants received the approved dose of letrozole 2.5 mg QD administered continuously with PF-07220060.

[0143] The objective of Part 2C is to evaluate the tolerability, safety, and preliminary antitumor activity of PF-07220060 in combination with fulvestrant. Part 2C is a dose expansion of PF-07220060 in combination with fulvestrant at the doses specified in Part 1C in participants with HR-positive, HER2-negative advanced / metastatic breast cancer whose disease has progressed on prior treatment. Participants who have received prior treatment with CDK4 / 6 inhibitors, fulvestrant, everolimus, and any agent whose MOA inhibits the PI3k-mTOR pathway are excluded. In Part 2C, participants will receive two IM injections of fulvestrant (250 mg each) before receiving oral PF-07220060.

[0144] Additional dosing regimens determined to be safe by the BLRM in Parts 1B and 1C may be investigated in Parts 2B and 2C to help identify optimal dosing regimens of PF-07220060 in combination with letrozole or fulvestrant (e.g., different starting doses or different schedules).

[0145] Method of administration: PF-07220060 Oral PF-07220060 was administered on an empty stomach with at least 8 ounces (240 mL) of water (except during the food effect assessment on Day 7 prior to Part 1D). For BID dosing, no food or liquids other than water were permitted 2 hours before and 1 hour after each dose throughout the study. For QD dosing, no food or liquids other than water were permitted 2 hours before and 2 hours after each dose throughout the study.

[0146] PF-07220060 for oral administration was provided as immediate release tablets of 5 mg, 25 mg, 100 mg, 125 mg, and 200 mg.

[0147] In Part 1D only, PF-07220060 was administered on Day 7 prior to Cycle 1 and on Day 1 of Cycle 1 after an overnight fast of at least 10 hours. On Day 7 prior to Cycle 1 (fed state), a study breakfast (described below) was provided and must be consumed within 30 minutes. PF-07220060 was administered 30 minutes after the start of the meal with approximately 8 ounces of water. No additional meals were permitted until at least 4 hours after dosing. On Day 1 of Cycle 1, participants received another single oral dose of PF-07220060 under fasting conditions after an overnight fast of at least 10 hours. PF-07220060 was administered with 8 ounces of water. No meals were permitted for an additional 4 hours after dosing. Ad libitum access to water was permitted on both treatment days, except 1 hour before and 1 hour after drug administration. Beginning on Day 1 of Cycle 1, PF-07220060 was administered on an empty stomach with at least 8 ounces of water, with no food or liquids other than water permitted 2 hours before and 2 hours after dosing.

[0148] The test breakfast was a high-fat (approximately 50% of the total calorie content of the meal) and high-calorie (approximately 800-1000 calories) meal, providing approximately 150, 250, and 500-600 kcal of protein, carbohydrate, and fat, respectively.

[0149] Fulvestrant Fulvestrant (Faslodex®) is available in two 5 mL clear neutral glass (Type 1) barrels, each containing a 250 mg / 5 mL solution of fulvestrant for intramuscular injection, fitted with a tamper-evident cap. The syringes are in a tray with polystyrene plunger rods and safety needles (SafetyGlide™) for connection to the barrels.

[0150] Fulvestrant injections were completed prior to administration of PF-07220060. Fulvestrant was administered intramuscularly as two 5 mL injections administered slowly (1-2 minutes per injection) into the buttocks on days 1 and 15 during cycle 1 and on day 1 (± 3 days) of each 28-day cycle thereafter, according to the Faslodex® label instructions.

[0151] Participants in Part 1C who received fulvestrant as part of their most recent prior therapy were only required to receive a dose on day 1 of cycle 1 (i.e., no dose was required on day 15). Day 1 of cycle 1 was approximately 28 days after their most recent dose of fulvestrant.

[0152] Letrozole Letrozole (Femara®) was available as 2.5 mg tablets.

[0153] Letrozole was administered orally once daily (2.5 mg QD) continuously with PF-07220060. Letrozole did not need to be administered simultaneously with PF-07220060.

[0154] Midazolam Midazolam is a benzodiazepine used clinically for conscious sedation. It is specifically metabolized by CYP3A and is widely used as an in vivo probe of CYP3A activity. Oral formulations of midazolam are used to evaluate their effects on CYP3A activity in the GI tract and liver. The information obtained will be used to determine whether restrictions or dose modifications of concomitant medications are appropriate in future studies.

[0155] Participants will refrain from eating and consuming liquids other than water 2 hours before and 1 hour after midazolam administration. Participants will receive a 2 mg midazolam dose orally with 8 ounces (240 mL) of water on days 1 and 15 prior to cycle 1 for DDI assessment. Midazolam will be administered only twice.

[0156] I. Pharmacokinetic (PK) studies In an ongoing Phase 1 / 1b study, preliminary PK data for PF-07220060 as monotherapy (Part 1A) and in combination with endocrine therapy (Part 1B and Part 1C) were available from 60 participants with advanced solid tumors as of August 30, 2022. PF-07220060 was administered orally at doses ranging from 100 to 500 mg BID as a single agent and at 300 to 400 mg BID in combination with letrozole or fulvestrant. Available plasma concentration-time data for PF-07220060 were analyzed using noncompartmental methods.

[0157] A preliminary noncompartmental PK analysis was performed based on available samples collected from study participants. Figure 1 shows the plasma concentration-time profile of PF-07220060 on day 1 after oral BID administration. Figure 2 shows the plasma concentration-time profile of PF-07220060 on day 15 after oral BID administration. Table 4 provides an overview of the PK parameters of PF-07220060 as monotherapy and in combination with letrozole or fulvestrant.

[0158] [Table 5]

[0159] Preliminary PK results indicate that PF-07220060 is rapidly absorbed following oral administration and has T max The median duration of the drug was 1-4 hours. max , AUC, and C min Exposure parameters, including PK, generally increased as dose increased from 100 to 300 mg BID on both cycle 1 day 1 and cycle 1 day 15. No further increases in exposure parameters were observed at doses above 300 mg BID. Moderate accumulation of AUC was observed after repeated BID dosing. In general, PF-07220060 showed moderate inter-subject variability in exposure parameters. The PK of PF-07220060 as monotherapy and in combination with letrozole or fulvestrant was generally comparable.

[0160] II. Safety Dose-limiting toxicity (DLT) As of September 2, 2022, of 55 evaluable participants, 4 (7.3%) participants experienced a DLT: 2 participants in the PF-07220060 monotherapy 500 mg BID cohort experienced a DLT of grade 3 thrombocytopenia, 1 participant in the PF-07220060 monotherapy 200 mg BID cohort experienced a DLT of grade 3 neutropenia, and 1 participant in the PF-07220060 combination with fulvestrant 400 mg BID cohort experienced a DLT of grade 3 neutropenia lasting ≥5 days.

[0161] Adverse events Adverse events in patients receiving PF-07220060 in the Phase 1 / 1b clinical trial were assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. As of September 2, 2022, the following adverse event data were available:

[0162] All causally related treatment-emergent adverse events (TEAEs) A total of 375 causally related all-cause TEAEs were reported in 59 of 66 participants (89.4%) who received PF-07220060 in Part 1A, Part 1B, Part 1C, and Part 1D.

[0163] In Part 1A (single-agent PF-07220060), a total of 32 (94.1%) of 34 participants reported any causal-related TEAE. The most commonly reported (≥20%) all causal TEAEs across all dose levels were neutropenia (41.2%), anemia, diarrhea, leukopenia (35.3% each), nausea (29.4%), increased aspartate aminotransferase, and vomiting (20.6% each). A total of 15 grade ≥3 all causal TEAEs were reported across all dose levels. The most commonly reported (≥5%) grade ≥3 all causal TEAEs were neutropenia (14.7%), anemia, increased aspartate aminotransferase, COVID-19, diarrhea, leukopenia, thrombocytopenia, and syncope (5.9% each). No grade 4 TEAEs were reported. One participant in the 400 mg BID group experienced a grade 5 all-cause related TEAE (respiratory failure; unrelated to study drug PF-07220060).

[0164] In Part 1B (PF-07220060 in combination with letrozole), 10 of 13 participants (76.9%) reported any causal related TEAE. The most commonly reported (≥20%) causal related TEAEs were diarrhea (38.5%), fatigue (30.8%), and nausea, neutropenia, and sinusitis (23.1% each). Across all dose levels, one participant (7.7%) reported a grade 3 causal related TEAE, including anemia, leukopenia, and neutropenia (7.7% each). No grade 4 or grade 5 causal related TEAEs were reported.

[0165] In Part 1C (PF-07220060 in combination with fulvestrant), 13 of 13 participants (100%) experienced at least one causal all-related TEAE. The most commonly reported (≥20%) causal all-related TEAEs were neutropenia (53.8%), diarrhea, leukopenia, and nausea (46.2% each), thrombocytopenia and hyperglycemia (30.8% each), anemia, fatigue, and vomiting (23.1% each). A total of seven grade 3 causal all-related TEAEs were reported across all dose levels, including neutropenia (23.1%), leukopenia (15.4%), and anemia, nausea, and biliary tract infection (7.7% each). No grade 4 or 5 TEAEs were reported.

[0166] In Part 1D (single-agent PF-07220060, 400 mg BID, diet cohort), 4 of 6 participants (66.7%) reported TEAEs. The most commonly reported (≥20%) causally related all TEAEs were diarrhea, leukopenia, and neutropenia (50.0% each). No grade 3 and 5 TEAEs were reported. One participant reported a grade 4 causally related all TEAE (respiratory failure).

[0167] Treatment-related, treatment-emergent adverse events Fifty-four of 66 (81.8%) participants who received PF-07220060 as a single agent in dose escalation in Part 1 reported any treatment-related TEAEs. Overall, the most commonly reported (≥20%) treatment-related TEAEs were neutropenia (40.9%), diarrhea (33.3%), leukopenia (30.3%), nausea (27.3%), and anemia (21.2%).

[0168] In Part 1A (single-agent PF-07220060), 27 of 34 participants (79.4%) experienced at least one treatment-related TEAE.

[0169] The most commonly reported (≥10%) treatment-related TEAEs across all dose levels were neutropenia (41.2%), anemia and leukopenia (29.4% each), nausea (26.5%), diarrhea (23.5%), thrombocytopenia (20.6%), vomiting (14.7%), and fatigue (11.8%). A total of 9 (26.5%) participants had grade 3 treatment-related TEAEs. The most commonly reported (≥5%) grade 3 treatment-related TEAEs were neutropenia (14.7%), anemia, diarrhea, leukopenia, and thrombocytopenia (5.9% each). No grade 4 or grade 5 treatment-related TEAEs were reported.

[0170] In Part 1B (PF-07220060 in combination with letrozole), a total of 10 of 13 participants (76.9%) reported treatment-related TEAEs. The most commonly reported (≥20%) treatment-related TEAEs were diarrhea (38.5%), fatigue (30.8%), nausea, and neutropenia (23.1% each). One participant (7.7%) across the cohort reported a grade 3 treatment-related TEAE, including anemia, leukopenia, and neutropenia (7.7% each). No grade 4 or grade 5 TEAEs were reported.

[0171] In Part 1C (PF-07220060 in combination with fulvestrant), all 13 participants (100%) experienced at least one treatment-related TEAE. The most commonly reported (≥20%) treatment-related TEAEs were neutropenia (53.8%), diarrhea and leukopenia (46.2% each), nausea (38.5%), hyperglycemia (30.8%), anemia, fatigue, vomiting, and thrombocytopenia (23.1% each). A total of 6 of the 13 participants (46.2%) experienced grade 3 treatment-related TEAEs. Grade 3 treatment-related TEAEs reported were neutropenia (23.1%), leukopenia (15.4%), and anemia and nausea (7.7% each). No grade 4 or 5 TEAEs were reported.

[0172] In Part 1D (single-agent PF-07220060, 400 mg BID, diet cohort), a total of 4 of 6 participants (66.7%) reported treatment-related TEAEs. The most commonly reported (≥20%) treatment-related TEAEs were diarrhea, leukopenia, and neutropenia (50.0% each). No grade 3, 4, or 5 treatment-related TEAEs were reported.

[0173] Safety Conclusion: Available safety results support the ongoing clinical development of PF-07220060 to treat HR+ HER2- advanced or mBC, as well as other tumors with the potential for CDK4-dependent growth, including adenocarcinoma of NSCLC, prostate cancer, CRC, liposarcoma, and tumors with previous confirmed CDK4 or CCND1 amplification according to local standard testing.

[0174] III. Effectiveness Efficacy data were available from 70 evaluable patients. As of October 15, 2022, PF-06873600 demonstrated a disease control rate of 65.7% (n=65.7 / 100) in evaluable patients across all cohorts. This included one participant with a confirmed complete response and six participants with a confirmed partial response. Among evaluable patients evaluated according to RECIST version 1.1 (Table 5), disease control rates were 57.9% (n=22 / 38) in the PF-07220060 monotherapy arm (total Part 1A) and 80.8% (n=21 / 26) in the PF-07220060 + endocrine therapy combination arm (Part 1B + Part 1C).

[0175] [Table 6-1]

[0176] [Table 6-2]

[0177] [Table 6-3]

[0178] PF-07220060 has shown early signs of antitumor activity when combined with endocrine therapy in the HR+ / Her2- metastatic breast cancer population. Efficacy evaluation in dose expansion cohorts in RDE when combined with fulvestrant and letrozole is currently ongoing.

Claims

1. 1. A method of treating cancer comprising orally administering a therapeutically effective amount of PF-07220060, or a pharma- ceutically acceptable salt thereof, to a subject in need of such treatment, wherein said therapeutically effective amount is about 100 mg to about 500 mg twice daily (BID).

2. 10. The method of claim 1, wherein the therapeutically effective amount is from about 300 mg to about 500 mg BID.

3. 3. The method of claim 1 or 2, wherein the therapeutically effective amount is about 300 mg BID.

4. 3. The method of claim 1 or 2, wherein the therapeutically effective amount is about 400 mg BID.

5. 5. The method of any one of claims 1 to 4, wherein PF-07220060 is administered continuously.

6. The method of any one of claims 1 to 5, wherein PF-07220060 is administered in the form of a tablet or capsule.

7. 1. A method of treating cancer comprising administering to a subject in need of cancer treatment a therapeutically effective amount of a pharmaceutical composition comprising PF-07220060 and an endocrine therapy agent, wherein said therapeutically effective amount of PF-07220060 is from about 100 mg to about 500 mg BID.

8. 8. The method of claim 7, wherein the endocrine therapy agent is an aromatase inhibitor, an androgen receptor inhibitor, a selective estrogen receptor degrader (SERD), or a selective estrogen receptor modulator (SERM).

9. 8. The method of claim 7, wherein the endocrine therapy agent is selected from the group consisting of letrozole, anastrozole, exemestane, fulvestrant, elacestrant, amsenestrant, diredestrant, RG6171, camizestrant, AZD9496, lindestrant, ZN-c5, LSZ102, D-0502, LY3484356, SHR9549, tamoxifen, raloxifene, toremifene, lasofoxifene, bazedoxifene, and afimoxifene.

10. 8. The method of claim 7, wherein the endocrine therapy is letrozole or fulvestrant.

11. 11. The method of any one of claims 7 to 10, wherein the subject is administered the endocrine therapy agent, followed by administration of PF-07220060.

12. 10. The method of claim 1 or 7, wherein the subject has been previously treated with chemotherapy, radiation therapy, and / or surgical resection.

13. The method of claim 1 or 7, wherein the subject has been previously treated with a CDK4 / 6 inhibitor.

14. 10. The method of claim 1 or 7, wherein the subject has been previously treated with an endocrine therapy agent.

15. The method of claim 1 or 13, wherein the subject is a mammal.

16. 16. The method of any one of claims 1 to 15, wherein the subject is suffering from breast cancer, ovarian cancer, fallopian tube cancer, primary peritoneal cancer, bladder cancer, uterine cancer, prostate cancer, lung cancer, esophageal cancer, head and neck cancer, colorectal cancer, kidney cancer, liver cancer, pancreatic cancer, gastric cancer, and thyroid cancer.

17. 17. The method of any one of claims 1 to 16, wherein the cancer is breast cancer selected from any one or more of hormone receptor positive (HR+), hormone receptor negative (HR-), human epidermal growth factor receptor 2 negative (HER2-), human epidermal growth factor receptor 2 positive (HER2+), HR+ / HER2-, ER- / HR+, ER+ / HER2-, and triple negative breast cancer (TNBC).

18. 17. The method of any one of claims 1 to 16, wherein the cancer is NSCLC, prostate cancer, colorectal cancer, liposarcoma, or a tumor characterized by amplification or overexpression of CDK4 and / or CCND1.

19. 1. Use of PF-07220060 in the manufacture of a medicament for use in treating cancer in a subject in need thereof, wherein said medicament is administered in an amount of about 100 mg to about 500 mg BID as a therapeutically effective unit dose of PF-07220060.

20. 1. Use of PF-07220060 and an endocrine therapeutic agent in the manufacture of a medicament for use in treating cancer in a subject in need thereof, wherein said medicament is administered in an amount of about 100 mg to about 500 mg BID as a therapeutically effective unit dose of PF-07220060.

21. 1. A medicament for use in treating cancer in a subject in need thereof, comprising a therapeutically effective amount of PF-07220060, wherein said therapeutically effective amount is from about 100 mg to about 500 mg BID.

22. 1. A pharmaceutical product comprising a therapeutically effective amount of PF-07220060 and an endocrine therapeutic agent for use in treating cancer in a subject in need thereof, wherein said therapeutically effective amount is from about 100 mg to about 500 mg BID.

Citation Information

Patent Citations

  • 2-Amino-pyridine or 2-amino-pyrimidine derivatives as cyclin-dependent kinase inhibitors

    JP2021522275A